Back

Residual thrombotic risk: from monotherapy to dual pathway inhibition.

29 August 2022 (14:30 - 14:45)
Organised by:
Congress Presentation Part of: How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Bianca Rocca

LUM University, Casamassima (Italy)

4 More presentations in this session

Presentation thumbnail
Residual risk in dyslipidaemias: from statins to PCSK9 inhibitors and beyond.
Professor E. Stroes (Amsterdam, NL)
Slides Video
Presentation thumbnail
Residual inflammatory risk.
Professor W. Koenig (Munich, DE)
Slides Video
Presentation thumbnail
Residual diabetic risk: from glucose lowering to cardiovascular protection.
Professor N. Marx (Aachen, DE)
Slides Video
Presentation thumbnail
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options – discussion.
Video

Access the full session

Session thumbnail
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 14:30 CET
You may be interested in
thumbnail
Congress Session
Beyond stenting: optimising adjunctive pharmacotherapy for myocardial infarction
30 August 2025
thumbnail
Congress Presentation
Managing stroke patients with indications for both anticoagulant and antiplatelet treatment
31 August 2024
thumbnail
Congress Presentation
Dual pathway inhibition in patients with atherosclerosis with and without heart failure: insights from the XATOA Registry
31 August 2024
thumbnail
Congress Presentation
Thrombosis and antithrombotic treatment.
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources